Ann: PTX successful immunogenicity testing of OmniCAR, page-79

Excellent result and progression on the OmniCar platform.

The following captures this:


>The results demonstrated that both SpyTag and SpyCatcher have very low immunogenicity - lower than a panel of humanised therapeutic antibodies already approved for human use and on par with circulating human antibodies. It is worth noting that in silico immunogenicity testing is widely recognised as being over-predictive as contemporary algorithms are unable to account for cellular antigen processing.<

In essence, the low immunogenicity, support the equivalent or so on already in use parameters of antibodies, and hence provides the confidence toward next method of safety testing.

Some may respond on the methodology used, yet as a standardised method of a precursor to tolerance diversity and marker, then the result did what it was meant to do ( in fact, remarkably well).

With each step, not only de-risking but technological validation occurs. Possibility more evident on the academic and corporate side of things. Yet, as SYC stated, onlookers’ interests on such a platform are there. And, although we have 3 pre-clinical projects due, such and further validation may even see pen-on-paper offers at the pre-clinical stage.

On a lighter note, and less speculative, i’m Wondering if Steve ( on occasions) still pinches ‘himself’ at the fact that ptx has such a potential platform in OmniCar.